Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.63 |
| ▸ | PLA2G6 | O60733 | 2/20 | 0.51 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19540551 | 1.00 | FASN (0.63) | FASNPLA2G6PLA2G4ACTRB1CYP3A4 | |
| SCHEMBL6823187 | 0.88 | PLA2G6 (0.62) | FASNPLA2G6PLA2G4ANAAAABCB1 | |
| SCHEMBL6824441 | 0.88 | PLA2G6 (0.62) | FASNPLA2G6PLA2G4ANAAAABCB1 | |
| SCHEMBL10368775 | 0.87 | PLA2G6 (0.61) | FASNPLA2G6PLA2G4ANAAAABCB1 | |
| SCHEMBL10369079 | 0.87 | PLA2G6 (0.61) | FASNPLA2G6PLA2G4ANAAAABCB1 | |
| SCHEMBL10368566 | 0.87 | PLA2G6 (0.61) | FASNPLA2G6PLA2G4ANAAAABCB1 | |
| SCHEMBL15012876 | 0.80 | FASN (0.81) | FASNPLA2G6PLA2G4ACTRB1CYP3A4 | |
| SCHEMBL15012874 | 0.80 | FASN (0.81) | FASNPLA2G6PLA2G4ACTRB1CYP3A4 | |
| SCHEMBL15256957 | 0.79 | FASN (0.48) | FASNPLA2G6PLA2G4ACYP3A4 | |
| SCHEMBL10073526 | 0.77 | FASN (1.00) | FASNPLA2G6PLA2G4ACTRB1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024050-A1 | Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation | BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2004-02-05 | — | — | US | disclosed |
| WO-2003088975-A1 | INHIBITION OF FATTY ACID SYNTHASE BY BETA-LACTONES AND OTHER COMPOUNDS FOR INHIBITION OF CELLULAR PROLIFERATION | THE BURNHAM INSTITUTE (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024050-A1 | Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation | FASN, FADS1, FADS2 | FASN 1/4885PLA2G6 600/4885PLA2G4A 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.